Citeline Data Shows Higher Rate of Transparency Commitment
Citeline reported that clinical trial transparency is in a much healthier state than shown in previous studies.
Citeline, a pharmaceutical industry research provider on clinical trials, reported that clinical trial transparency, also known as responsible data sharing, is in a much healthier state than shown in previous studies. Doro Shin, a Citeline analyst, presented the findings of her analysis at an event for competitive intelligence experts in the pharmaceutical industry. For her analysis, Ms. Shin used Citeline's Trialtrove, a competitive intelligence resource which draws data from over 30,000 sources. The analysis focused on nearly 7,500 Phase II-III industry sponsored trials with primary completion dates between 2008 and 2012, to determine how many of these trials provided results in peer reviewed sources (defined as a journal manuscript or conference abstract) or at clinicaltrials.gov.
Out of all the Phase II-III studies reviewed, a surprising 78% provided final or interim results across all sources. When looking just at the Phase III trials, the most expensive and high profile trials for sponsor companies, this number improves and 81% provide final or interim results. Prior industry analyses found that 23-57% of completed clinical trials do not report results.
Read the full release here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.
